Pediatric Patients with Eosinophilic Esophagitis and Their Parents Identify Symptoms as the Most Important Treatment Outcome.

Core outcome set Endpoints Eosinophilic esophagitis Parents’ perspective Pediatric patients’ perspective Therapy goals

Journal

International archives of allergy and immunology
ISSN: 1423-0097
Titre abrégé: Int Arch Allergy Immunol
Pays: Switzerland
ID NLM: 9211652

Informations de publication

Date de publication:
06 Mar 2024
Historique:
received: 31 01 2023
accepted: 09 11 2023
medline: 7 3 2024
pubmed: 7 3 2024
entrez: 6 3 2024
Statut: aheadofprint

Résumé

Given the lack of data, we aimed to explore which therapeutic endpoints pediatric patients with eosinophilic esophagitis (EoE) and their parents consider to be relevant. We created an educational brochure on EoE and a questionnaire, both of which were content-validated by pediatric patients and parents. Validated documents were sent to 112 patients and parents. They ranked the importance (5 levels) of short (during next 3 months) and long-term (≥1 year) treatment effect on symptoms, quality of life, endoscopic inflammation, stricture formation, histological inflammation, and fibrosis. A total of 45 parents and 30 pediatric patients ≥11 years completed the questionnaires. Pediatric patients identified improvement in the following domains as most important in the short- and long-term, respectively: symptoms (73% vs. 77%), QoL (53% vs. 57%), histologic inflammation (47% vs. 50%), histologic fibrosis (40% vs. 33%), endoscopic inflammation (47% vs. 40%), and strictures (33% vs. 40%). Parents of children ≥11 years old classified improvement in the following domains as most important in the short- and long-term, respectively: symptoms (70% vs. 83%), QoL (63% vs. 80%), histologic inflammation (67% vs. 77%), histologic fibrosis (47% vs. 63%), endoscopic inflammation (77% vs. 80%), and strictures (40% vs. 53%). Agreement between caregiver and children on the short-term importance of treatment outcomes was as follows: symptoms (77%), QoL (40%), histologic inflammation and fibrosis (47% and 43%), endoscopic inflammation and strictures (50% and 40%). Pediatric patients and parents attributed most importance to improvement in symptoms and QoL. Agreement between parents and patients regarding therapy goals is limited.

Identifiants

pubmed: 38447548
pii: 000535242
doi: 10.1159/000535242
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

1-9

Informations de copyright

© 2024 S. Karger AG, Basel.

Auteurs

Thea von Graffenried (T)

Division of Pediatric Gastroenterology and Hepatology, Department of Pediatrics, Centre Hospitalier Universitaire Vaudois (CHUV), Lausanne, Switzerland.

Ekaterina Safroneeva (E)

Institute of Social and Preventive Medicine, University of Bern, Bern, Switzerland.
Tillotts Pharma AG, Rheinfelden, Switzerland.

Christian Braegger (C)

Division of Pediatric Gastroenterology and Hepatology, Department of Pediatrics, University Children's Hospital Zurich, Zurich, Switzerland.

Jessica Ezri (J)

Division of Pediatric Gastroenterology and Hepatology, Department of Pediatrics, Centre Hospitalier Universitaire Vaudois (CHUV), Lausanne, Switzerland.

Luca Garzoni (L)

Department of Pediatrics, Clinique des Grangettes, Geneva, Switzerland.

Alexa Giroud Rivier (A)

Division of Pediatric Gastroenterology and Hepatology, Department of Pediatrics, Centre Hospitalier Universitaire Vaudois (CHUV), Lausanne, Switzerland.

Thomas Greuter (T)

Division of Gastroenterology and Hepatology, Centre Hospitalier Universitaire Vaudois (CHUV) and University of Lausanne, Lausanne, Switzerland.
Department of Gastroenterology and Hepatology, University Hospital Zurich, Zurich, Switzerland.

Henrik Köhler (H)

Division of Pediatric Gastroenterology and Hepatology, Department of Pediatrics, Children's Hospital of Aarau, Aarau, Switzerland.

Valerie A McLin (VA)

Division of Pediatric Gastroenterology and Swiss Pediatric Liver Center, Department of Pediatrics, University Hospitals Geneva, Geneva, Switzerland.

George Marx (G)

Division of Pediatric Gastroenterology and Hepatology, Department of Pediatrics, Children's Hospital of Eastern Switzerland, St. Gallen, Switzerland.

Pascal Müller (P)

Division of Pediatric Gastroenterology and Hepatology, Department of Pediatrics, Children's Hospital of Eastern Switzerland, St. Gallen, Switzerland.

Laetitia Marie Petit (LM)

Division of Pediatric Gastroenterology and Swiss Pediatric Liver Center, Department of Pediatrics, University Hospitals Geneva, Geneva, Switzerland.

Susanne Schibli (S)

Division of Pediatric Gastroenterology, Hepatology and Nutrition, Children's Hospital, Inselspital, Bern, Switzerland.

Christiane Sokollik (C)

Division of Pediatric Gastroenterology, Hepatology and Nutrition, Children's Hospital, Inselspital, Bern, Switzerland.

Michela Tempia-Caliera (M)

Department of Pediatrics, Clinique des Grangettes, Geneva, Switzerland.

Marcel Zwahlen (M)

Institute of Social and Preventive Medicine, University of Bern, Bern, Switzerland.

Alain M Schoepfer (AM)

Division of Gastroenterology and Hepatology, Centre Hospitalier Universitaire Vaudois (CHUV) and University of Lausanne, Lausanne, Switzerland, alain.schoepfer@chuv.ch.

Andreas Nydegger (A)

Division of Pediatric Gastroenterology and Hepatology, Department of Pediatrics, Centre Hospitalier Universitaire Vaudois (CHUV), Lausanne, Switzerland.

Classifications MeSH